Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Gross Profit (2016 - 2025)

Ligand Pharmaceuticals' Gross Profit history spans 16 years, with the latest figure at $56.7 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 41.77% year-over-year to $56.7 million; the TTM value through Dec 2025 reached $253.5 million, up 62.46%, while the annual FY2025 figure was $253.5 million, 62.46% up from the prior year.
  • Gross Profit for Q4 2025 was $56.7 million at Ligand Pharmaceuticals, down from $111.7 million in the prior quarter.
  • Across five years, Gross Profit topped out at $111.7 million in Q3 2025 and bottomed at $24.7 million in Q2 2023.
  • The 5-year median for Gross Profit is $40.1 million (2023), against an average of $42.7 million.
  • The largest annual shift saw Gross Profit tumbled 35.24% in 2022 before it skyrocketed 126.2% in 2025.
  • A 5-year view of Gross Profit shows it stood at $44.4 million in 2021, then crashed by 35.24% to $28.8 million in 2022, then dropped by 8.02% to $26.5 million in 2023, then surged by 51.08% to $40.0 million in 2024, then surged by 41.77% to $56.7 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Gross Profit are $56.7 million (Q4 2025), $111.7 million (Q3 2025), and $44.7 million (Q2 2025).